Published in Arterioscler Thromb Vasc Biol on January 07, 2016
Simultaneous Platelet P2Y12 and P2Y1 ADP Receptor Blockade: Are Two Better Than One? Arterioscler Thromb Vasc Biol (2016) 0.75
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med (2001) 20.20
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Receptors for purines and pyrimidines. Pharmacol Rev (1998) 13.92
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16
Intravenous platelet blockade with cangrelor during PCI. N Engl J Med (2009) 3.31
Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med (2009) 2.52
Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci U S A (1998) 2.42
Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem (1998) 2.32
Presence of diadenosine 5',5''' -P1, P4-tetraphosphate (Ap4A) in mamalian cells in levels varying widely with proliferative activity of the tissue: a possible positive "pleiotypic activator". Proc Natl Acad Sci U S A (1976) 2.29
Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol (2004) 1.94
2-Chloro N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate is a selective high affinity P2Y(1) receptor antagonist. Br J Pharmacol (2002) 1.52
The presence of diadenosine 5',5'''-P1,P3-triphosphate (Ap3A) in human platelets. Biochem Biophys Res Commun (1983) 1.49
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation (2011) 1.33
Two disparate ligand-binding sites in the human P2Y1 receptor. Nature (2015) 1.25
Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets. Blood (2004) 1.25
Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J (2011) 1.23
The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther (2005) 1.18
Analogues of diadenosine 5',5'''-P1,P4-tetraphosphate (Ap4A) as potential anti-platelet-aggregation agents. Proc Natl Acad Sci U S A (1992) 1.13
Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications. Clin Pharmacokinet (2012) 1.12
Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemost (2009) 1.10
Purification and functional reconstitution of the human P2Y12 receptor. Mol Pharmacol (2003) 1.05
P1,P4-dithio-P2,P3-monochloromethylene diadenosine 5',5'''-P1,P4-tetraphosphate: a novel antiplatelet agent. Proc Natl Acad Sci U S A (1997) 1.00
Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost (2006) 0.99
An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation (1991) 0.99
Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. Thromb Res (2009) 0.96
Brief antecedent ischemia attenuates platelet-mediated thrombosis in damaged and stenotic canine coronary arteries: role of adenosine. Circulation (1998) 0.93
Identification and quantification of diadenosine polyphosphate concentrations in human plasma. Arterioscler Thromb Vasc Biol (2003) 0.90
Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation. J Thromb Haemost (2012) 0.90
The P2Y1 receptor plays an essential role in the platelet shape change induced by collagen when TxA2 formation is prevented. J Thromb Haemost (2004) 0.90
Effect of adenosine A2 receptor stimulation on platelet activation-aggregation: differences between canine and human models. Thromb Res (2007) 0.87
P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents. Eur Heart J (2006) 0.80
Synthesis and biological activity of 2-alkylated deoxyadenosine bisphosphate derivatives as P2Y(1) receptor antagonists. Bioorg Med Chem (2004) 0.80
New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. Eur J Med Chem (2015) 0.78